PLA2R-Associated Membranous Nephropathy: Antibody Reactivity to 123 Linear Peptides

A serological study investigating antibodies against linear peptides of the phospholipase A2 receptor (PLA2R) in patients with membranous nephropathy. The dataset includes results from ELISA tests on 42 anti-PLA2R-negative patients and 32 anti-PLA2R-positive patients, measuring IgG reactivity to 123 synthesized peptides. The research was authored by Miao Wang and shared on figshare under a CC-BY-4.0 license.

Use Cases

• Identify candidate peptide biomarkers for PLA2R-associated membranous nephropathy based on reported recognition frequencies for CysR-11, CTLD7-1, and CTLD7-2.
• Evaluate the sensitivity and specificity of peptide antibody assays for diagnosing seronegative cases based on the reported 43.7% sensitivity and 81.3% specificity.
• Compare antibody reactivity patterns between anti-PLA2R-negative and anti-PLA2R-positive patient cohorts based on the described differential recognition of peptides.
• Investigate the pathogenic relevance of linear epitopes in PLA2R-associated membranous nephropathy based on the inhibition assay results described.

Strengths

• Includes data from 42 biopsy-proven PLA2R-associated MN patients with negative circulating anti-PLA2R antibodies.
• Tests reactivity against 123 sequential overlapping linear peptides spanning the extracellular region of PLA2R.
• Reports specific recognition frequencies for individual peptides, such as CysR-11 (21.4%), CTLD7-1 (14.3%), and CTLD7-2 (16.7%).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small in scale (285.5 KB), indicating limited scope.

Provenance

Source

Miao Wang

Collection Method

ELISA measurements of circulating IgG antibodies to synthesized peptides in patient cohorts.

Freshness

Last updated 2026-05-28 06:17:13; freshness should be verified.